Gilead Sciences (NASDAQ: GILD) announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE